Twentyeight-Seven Therapeutics

United States
Primghar, Iowa, United States, 02139

Company profile

Twentyeight-Seven Therapeutics company profile

Twentyeight-Seven Therapeutics is a developer of microRNAs designed to target regulatory proteins.The company's modulating RNA which are short non-coding RNAs that inhibit target gene expression by suppressing mRNA translation and promoting mRNA decay and develop small molecules that can modulate levels of miRNAs by targeting proteins that interact with these miRNAs, enabling users to target miRNAs are directly involved in cancer initiation, progression, and metastasis.

Business identity

Phone number
617-331-7523
Operating status
Active
Company type
For Profit
Employee range
11-50 employees
Revenue range
$0-$1M
Founded
2016-01-01, Year

Headquarters

Postal code
02139
Country code
US
Continent
North America

Capital profile

Funding and company signals

Funding stage
Early Stage Venture
Funding rounds
3
Total equity funding
$80M
Last funding
Series A / $15M / 2019-05-09
Last equity funding
Series A / $15M
Investors
9
Lead investors
3
Founders
4
Articles
4

Founders and investors

Founders

Frank SlackGeorge DaleyPiotr SlizRichard Gregory

Lead investors

MPM CapitalNovartis Venture FundSofinnova Partners

Investors

Longwood FundMPM CapitalOUP (Osage University Partners)Sofinnova PartnersVertex Ventures